Search

rhIGFBP-3

rhIGFBP-3 (recombinant human insulin-like growth factor binding protein-3) is Insmed’s proprietary anti-cancer compound that has demonstrated significant decreases in cancerous growth in several models … It is developed by Insmed and is currently under phase I of the clinical trial.

Ridogrel

Ridogrel is a dual action drug useful for the prevention of systemic thrombo-embolism and as an adjunctive agent to thrombolytic therapy in acute myocardial infarction.

Dehydroascorbic acid

Dehydroascorbic acid as well as ascorbic acid are both termed Vitamin C, but the latter is the main form found in humans. … In the body, both dehydroascorbic acid and ascorbic acid have similar biological activity as antivirals but dehydroascorbic acid also has neuroprotective effects.

Acrizanib

Acrizanib is under investigation in clinical trial NCT02355028 (LHA510 Proof-of-concept Study as a Maintenance Therapy for Patients With Wet Age-related Macular Degeneration).

Deuterium oxide

Lentinan

ORG-34517

It has potential to treat a number of diseases such as Cushing’s disease, hypertension, diabetes, glaucoma etc, in which the activity of metabolites corticosterone and cortisol is high. … ORG-34517 is currently under investigation by Organon for the treatment of depression.

Phensuximide

Phensuximide is a member of the succinimide class with anticonvulsant properties. … The frequency of attacks is reduced by depression of nerve transmission in the motor cortex.

Luminol

Calcimycin

Primarily used as a biochemical tool for studying divalent cations in biological systems, Calcimycin also exhibits antibiotic activity against gram-positive bacteria and fungi. … It binds to and transports calcium and other divalent cations across membranes, disrupts oxidative phosphorylation, and inhibits ATPase in rat liver mitochondria.